| Literature DB >> 32716952 |
Jeong-Hoon Lim1, Man-Hoon Han2, Yong-Jin Kim2, Yena Jeon3, Hee-Yeon Jung1, Ji-Young Choi1, Jang-Hee Cho1, Chan-Duck Kim1, Yong-Lim Kim1, Hajeong Lee4, Dong Ki Kim4, Kyung Chul Moon5, Sun-Hee Park1.
Abstract
INTRODUCTION: Crescentic glomerulonephritis (CrGN) is a histologic feature of severe glomerular injury, clinically characterized by a rapid decline of renal function when not treated in a timely fashion. Factors associated with CrGN prognosis have not been thoroughly investigated. This study investigated the prognostic predictors of renal outcomes associated with CrGN, such as the histopathologic classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis, arteriosclerosis, and tertiary lymphoid organ (TLO) formation.Entities:
Mesh:
Year: 2020 PMID: 32716952 PMCID: PMC7384637 DOI: 10.1371/journal.pone.0236051
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Tertiary lymphoid organ formation in renal parenchyma.
PAS staining reveals nodular lymphoid aggregates. (A) Arrows indicate tertiary lymphoid organ formation. Original magnification ×50. (B) Original magnification ×200. (C) Original magnification ×400. Abbreviation: PAS, periodic acid-Schiff.
Baseline clinical and histopathologic characteristics.
| Variables | Total (n = 114) | ESRD (n = 55) | Non-ESRD (n = 59) | |
|---|---|---|---|---|
| Age (years) | 61.0 ± 15.3 | 64.0 ± 14.5 | 58.0 ± 15.7 | |
| Sex (% male) | 56 (49.1) | 29 (52.7) | 27 (45.8) | 0.457 |
| Comorbid disease, n (%) | ||||
| Diabetes | 14 (12.3) | 6 (10.9) | 8 (13.6) | 0.667 |
| Hypertension | 44 (38.6) | 27 (49.1) | 17 (28.8) | |
| Follow-up duration after biopsy (days) | 458.0 (92.5–1254.5) | 386.0 (77.0–1317.0) | 681.5 (134.3–1332.5) | 0.287 |
| Laboratory data | ||||
| Blood urea nitrogen (mg/dL) | 46.0 (31.0–65.6) | 57.2 (42.4–79.0) | 37.0 (27.5–58.0) | |
| Creatinine (mg/dL) | 4.1 (2.2–5.9) | 5.2 (4.0–7.8) | 2.6 (1.6–4.3) | |
| Estimated GFR (mL/min/1.73 m2) | 13.1 (8.2–25.7) | 8.6 (6.7–13.2) | 21.5 (12.9–36.1) | |
| CRP (mg/dL) | 2.8 (0.5–9.2) | 2.0 (0.3–6.3) | 3.4 (0.8–9.8) | 0.150 |
| Spot urine protein-to-creatinine ratio (g/g) | 2.4 (1.5–4.2) | 2.5 (1.6–4.9) | 2.3 (1.5–3.9) | 0.319 |
| Immunology, n (%) | ||||
| ANCA | 92 (80.7) | 45 (81.8) | 47 (79.7) | 0.771 |
| MPO-ANCA | 86 (93.5) | 41 (91.1) | 45 (95.7) | 0.831 |
| PR3-ANCA | 6 (6.5) | 4 (8.9) | 2 (4.3) | 0.427 |
| Anti-GBM antibody | 11 (9.6) | 5 (9.1) | 6 (10.2) | 0.845 |
| Histopathologic findings | ||||
| Number of glomeruli | 16.0 (12.0–22.3) | 16.0 (12.0–24.0) | 16.0 (12.0–22.0) | 0.337 |
| Normal glomeruli (%) | 21.6 (8.9–40.0) | 9.1 (0.0–23.1) | 33.3 (20.0–50.0) | |
| Crescentic glomeruli (%) | 51.3 (30.8–70.6) | 56.0 (33.3–76.0) | 47.8 (30.0–69.2) | 0.071 |
| Globally sclerotic glomeruli (%) | 15.4 (0.0–29.7) | 22.7 (7.7–40.0) | 10.0 (0.0–23.1) | |
| Histopathologic classification, n (%) | ||||
| Focal | 25 (21.9) | 4 (7.3) | 21 (35.6) | |
| Crescentic | 39 (34.2) | 19 (34.5) | 20 (33.9) | |
| Mixed | 34 (29.8) | 19 (34.5) | 15 (25.4) | |
| Sclerotic | 16 (14.0) | 13 (23.6) | 3 (5.1) | |
| Arteriosclerosis, n (%) | ||||
| Grade 0 (0–10%) | 45 (39.5) | 14 (25.5) | 31 (52.5) | |
| Grade 1 (10–25%) | 24 (21.1) | 12 (21.8) | 12 (20.3) | |
| Grade 2 (25–50%) | 27 (23.7) | 14 (25.5) | 13 (22.0) | |
| Grade 3 (>50%) | 18 (15.8) | 15 (27.3) | 3 (5.1) | |
| TLO formation, n (%) | 41 (36.0) | 29 (52.7) | 12 (20.3) | |
| Severe tubular atrophy (>50%), n (%) | 32 (28.1) | 24 (43.6) | 8 (13.6) | |
| Immune complex-mediated glomerulonephritis, n (%) | 9 (7.9) | 2 (3.6) | 7 (11.9) | 0.104 |
| Immunofluorescence | 19 (26.3) | 10 (18.2) | 9 (15.3) | 0.675 |
Values are shown as mean ± standard deviation or median (interquartile range).
aModerate to strong positive with antibody to at least one of the following: IgG, IgA, IgM, C3, and fibrinogen.
Abbreviations: ESRD, end-stage renal disease; GFR, glomerular filtration rate; CRP, C-reactive protein; ANCA, anti-neutrophil cytoplasmic antibody; MPO, myeloperoxidase; PR3, proteinase 3; GBM, glomerular basement membrane; TLO, tertiary lymphoid organ.
Fig 2Association between histopathologic classification and estimated GFR.
(A) eGFR at diagnosis. (B) eGFR at 1 year after diagnosis. Bars indicate median with interquartile range. Abbreviations: eGFR, estimated glomerular filtration rate.
Multivariable linear regression analysis of the change in eGFR during 1 year after diagnosis.
| Variables | β | SE | |
|---|---|---|---|
| Age | –0.44 | 0.11 | |
| Hypertension | –0.46 | 3.38 | 0.892 |
| eGFR at biopsy | –0.07 | 0.12 | 0.548 |
| Histopathologic classification | |||
| Focal | Reference | ||
| Crescentic | –6.41 | 4.61 | 0.167 |
| Mixed | –9.06 | 4.65 | 0.054 |
| Sclerotic | –13.48 | 5.77 | |
| Arteriosclerosis | |||
| Grade 0 | Reference | ||
| Grade 1 | 2.01 | 4.47 | 0.655 |
| Grade 2 | –4.21 | 4.41 | 0.343 |
| Grade 3 | –1.10 | 4.90 | 0.823 |
| TLO formation | 5.25 | 3.31 | 0.116 |
| Severe tubular atrophy | –5.98 | 3.76 | 0.115 |
Abbreviations: eGFR, estimated glomerular filtration rate; TLO, tertiary lymphoid organ.
Fig 3Comparison of renal survival.
(A) Renal survival according to histopathologic classification. (B) Renal survival according to severity of arteriosclerosis. (C) Renal survival according to TLO formation. Abbreviations: TLO, tertiary lymphoid organ.
Predictors for renal survival in Cox proportional hazards model.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age | 1.03 (1.01–1.06) | 1.03 (1.00–1.05) | ||
| Sex (ref: female) | 1.30 (0.76–2.21) | 0.336 | ||
| Diabetes | 0.98 (0.42–2.29) | 0.959 | ||
| Hypertension | 1.67 (0.98–2.84) | 0.058 | 0.86 (0.47–1.57) | 0.621 |
| Estimated GFR at biopsy | 0.91 (0.87–0.95) | 0.92 (0.88–0.97) | ||
| Histopathologic classification | ||||
| Focal | Reference | Reference | ||
| Crescentic | 3.56 (1.21–10.48) | 2.72 (0.87–8.62) | 0.084 | |
| Mixed | 5.05 (1.71–14.90) | 3.74 (1.18–11.82) | ||
| Sclerotic | 9.02 (2.90–28.02) | 4.84 (1.44–16.32) | ||
| Arteriosclerosis | ||||
| Grade 0 | Reference | Reference | ||
| Grade 1 | 2.08 (0.96–4.52) | 0.063 | 1.37 (0.57–3.25) | 0.483 |
| Grade 2 | 2.08 (0.99–4.37) | 0.053 | 1.24 (0.57–2.73) | 0.589 |
| Grade 3 | 4.40 (2.10–9.22) | 2.44 (1.04–5.77) | ||
| TLO formation | 2.21 (1.30–3.76) | 1.82 (1.03–3.21) | ||
| Severe tubular atrophy | 2.70 (1.57–4.64) | 0.99 (0.52–1.89) | 0.971 | |
| Glomerular Ig deposition by IF | 1.22 (0.62–2.43) | 0.566 | ||
Abbreviations: HR, hazard ratio; CI, confidence interval; GFR, glomerular filtration rate; TLO, tertiary lymphoid organ.; Ig, immunoglobulin; IF, immunofluorescence.
Fig 4Comparison of patient survival by histopathologic classification.
Predictors for patient death in Cox proportional hazards model.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age | 1.07 (1.03–1.11) | 1.08 (1.04–1.12) | ||
| Sex (ref: female) | 0.86 (0.43–1.72) | 0.855 | ||
| Diabetes | 1.05 (0.37–3.00) | 0.927 | 1.17 (0.39–3.51) | 0.775 |
| Hypertension | 0.61 (0.28–1.33) | 0.214 | 0.68 (0.12–1.54) | 0.314 |
| Estimated GFR at biopsy | 0.99 (0.96–1.02) | 0.451 | ||
| ANCA titer | 1.26 (0.93–1.71) | 0.133 | ||
| ANCA type (ref: PR3) | 2.20 (0.30–16.27) | 0.440 | ||
| Histopathologic classification | ||||
| Focal | Reference | Reference | ||
| Crescentic | 1.45 (0.45–4.70) | 0.539 | 1.87 (0.57–6.11) | 0.302 |
| Mixed | 2.10 (0.67–6.58) | 0.206 | 2.09 (0.65–6.66) | 0.214 |
| Sclerotic | 2.89 (0.87–9.62) | 0.083 | 4.96 (1.38–17.85) | |
| Arteriosclerosis | ||||
| Grade 0 | Reference | |||
| Grade 1 | 1.46 (0.59–3.57) | 0.412 | ||
| Grade 2 | 0.96 (0.38–2.44) | 0.931 | ||
| Grade 3 | 1.04 (0.37–2.96) | 0.939 | ||
| TLO formation | 0.74 (0.35–1.57) | 0.434 | ||
| Interstitial inflammation | 0.90 (0.63–1.30) | 0.577 | 0.70 (0.46–1.06) | 0.091 |
| Necrotizing lesions in glomeruli | 0.55 (0.21–1.43) | 0.221 | 0.81 (0.29–2.23) | 0.682 |
Abbreviations: HR, hazard ratio; CI, confidence interval; GFR, glomerular filtration rate; ANCA, anti-neutrophil cytoplasmic antibody; PR3, proteinase 3; TLO, tertiary lymphoid organ.